Posttransplant Immunotherapy With Donor Lymphocyte Infusions and Autologous Tumor Vaccines After HLA-Matched Transplant
- Determine time to relapse and overall survival of patients with high-risk acute myeloid
leukemia, acute lymphoblastic leukemia, or multiple myeloma treated with autologous
tumor cell vaccine with or without donor lymphocyte infusion after HLA-matched related
sibling nonmyeloablative hematopoietic stem cell transplantation.
- Evaluate the safety and tolerability of this regimen in these patients.
- Determine the maximum tolerated dose of donor lymphocyte infusions in these patients.
OUTLINE: Patients undergo collection of tumor cells for production of the cancer cell
vaccine and then undergo HLA-matched related sibling nonmyeloablative hematopoietic stem
cell transplantation (HSCT). Patients then receive cancer cell vaccine with or without donor
lymphocyte infusion. The donor lymphocytes are obtained from the same relative who donated
stem cells for the HSCT.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Time to relapse
Carol A. Huff, MD
Sidney Kimmel Comprehensive Cancer Center
United States: Federal Government
|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||Baltimore, Maryland 21231-2410|